In addition, CD9 functioning as a marker of PDAC tumor-initiating cells promotes plasma membrane localization of glutamine transporter ASCT2 to enhance glutamine uptake, contributing to organoid formation capability and tumor grafts in vivo [17]. This evidence concerns the gene CD9 and neoplasm.